Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nadunolimab - Cantargia

Next Previous
Drug Profile

Nadunolimab - Cantargia

Alternative Names: CAN-04; Nidanilimab - Cantargia

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University
  • Developer Cantargia; Pancreatic Cancer Action Network
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-1 receptor accessory protein inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours; Triple negative breast cancer

Most Recent Events

  • 05 Feb 2025 Pancreatic Cancer Action Network completes the Phase-III clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04229004)
  • 10 Dec 2024 Efficacy, adverse events and pharmacodynamics data from a phase Ib/II trial in Triple negative breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 13 Sep 2024 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top